RFA-AI-28-001-Full-Announcement.html

HTML file 185 KB Posted

Attached to
HIV/AIDS Clinical Trials Network Leadership and Operations Centers (UM1 Clinical Trial Required)
Opportunity number
RFA-AI-28-001
Issued by

About this file

This is a Request for Application (RFA) for HIV/AIDS Clinical Trials Network Leadership and Operations Centers, issued by the National Institute of Allergy and Infectious Diseases (NIAID) and partner NIH institutes. The funding opportunity (RFA-AI-28-001) seeks applications for four Leadership and Operations Centers (LOCs) to oversee research prioritization, planning, and conduct of HIV/AIDS clinical trials across four distinct research networks: HIV/AIDS Adult Therapeutics, HIV/AIDS Maternal/Adolescent/Pediatric, HIV Prevention, and Immune-Based Prevention. Each LOC will manage its network's research agenda while coordinating with Laboratory Centers, Statistical and Data Management Centers, and Clinical Trials Units. NIAID plans to commit an estimated $48 million total to fund 4 awards in FY2028, with each award providing 7-year project periods and an anticipated earliest start date of July 2027. Applications must be submitted electronically by February 09, 2027 at 5:00 PM local time; awards will follow scientific merit review and advisory council review with anticipated awards in October 2027 and December 2027.

The application requires a comprehensive Research Strategy organized into nine subsections addressing LOC overview and clinical research agenda (12-30 pages each), scientific leadership and governance structures, training and mentoring plans, evaluation and improvement metrics, quality management approaches, clinical operations, collaboration mechanisms with other network centers, and community engagement and communication strategies. Applicants must demonstrate experience managing complex clinical research programs, expertise in protocol design and regulatory compliance, and comprehensive plans for site selection and study implementation. Only applications proposing clinical trials are eligible; cost sharing is not required. Eligible applicants include higher education institutions, nonprofits with and without 501(c)(3) status, for-profit organizations, state and local governments, tribal governments, and faith-based organizations, though foreign organizations cannot serve as primary applicants. All applications must comply with standard NIH registration requirements (SAM, eRA Commons, Grants.gov, ORCID), undergo dual peer review for scientific and technical merit, and recipients must maintain compliance with 21 CFR Part 11, ICH E6 guidelines, and DAIDS clinical research policies throughout the award period.

RFA-AI-28-001-Full-Announcement.html

Text of this file

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases (NIAID)

Office of AIDS Research (OAR)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Aging (NIA)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

Applicants should carefully note which ICOs participate in this announcement and refer to NIH Institute, Center, and Office Grants & Funding Profiles for ICO-specific missions, interest areas, priorities, and funding considerations.

Funding Opportunity Title

HIV/AIDS Clinical Trials Network Leadership and Operations Centers (UM1 Clinical Trial Required)

Activity Code

UM1 Research Project with Complex Structure Cooperative Agreement

Announcement Type

Reissue of

RFA-AI-19-003

RFA-AI-19-004

RFA-AI-19-005

RFA-AI-19-006

Related Notices

Check for any recent Notices of NIH Policy Changes that may impact application requirements.

Funding Opportunity Number (FON)

RFA-AI-28-001

Companion Funding Opportunity

RFA-AI-28-002

, UM1

Research Project with Complex Structure Cooperative Agreement

RFA-AI-28-003

RFA-AI-28-004

Number of Applications

See Part 2, Section III. 3. Additional Information on Eligibility.

Assistance Listing Number(s)

93.8RP, 93.DE1, 93.HDR, 93.AGR, 93.242, 93.310, 93.853, 93.DA1, 93.HL2, 93.KRC

Funding Opportunity Purpose

The purpose of this notice of funding opportunity (NOFO) is to support HIV/AIDS Clinical Trials Network Leadership and Operations Centers (LOCs). Each LOC will oversee research prioritization, planning, and conduct of studies in a HIV/AIDS Clinical Trials Network to advance research in the prevention and treatment of HIV and HIV-associated diseases.

Funding Opportunity Goal(s)

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.

Key Dates

Posted Date

November 20, 2026

Open Date (Earliest Submission Date)

February 09, 2027

Application Due Dates
Review and Award Cycles
New
Renewal / Resubmission / Revision (as allowed)

AIDS - New/Renewal/Resubmission/Revision, as allowed

Scientific Merit Review
Advisory Council Review
Earliest Start Date

March 09, 2027

March 09, 2027

Not Applicable

July 2027
October 2027

December 2027

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

March 10, 2027

Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide, except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts).

Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.
Use the NIH ASSIST system to prepare, submit and track your application online.
Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.
Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.

Table of Contents

Part 1. Overview Information Key Dates Part 2. Full Text of Announcement Section I. Notice of Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV. Application and Submission Information Section V. Application Review Information Section VI. Award Administration Information Section VII. Agency Contacts Section VIII. Other Information

Part 2. Full Text of Announcement

Section I. Notice of Funding Opportunity Description

Network Scope and Structure The National Institute of Allergy and Infectious Diseases (NIAID) and its Institute, Center, and Office (ICO) partners will support four clinical trials networks with unique research agendas that will conduct HIV/AIDS prevention, treatment and implementation science research, improving uptake of evidence-based strategies across the lifespan:

HIV/AIDS Adult Therapeutics Clinical Trials Network

HIV/AIDS Maternal, Adolescent and Pediatric Clinical Trials Network

HIV Prevention Clinical Trials Network

Immune-Based Prevention Clinical Trials Network

Each HIV/AIDS Clinical Trial Network is composed collectively of the following clinical trial infrastructure designed to support a complex clinical research agenda:

RFA-AI-28-001 - HIV/AIDS Clinical Trials Network Leadership and Operations Centers (LOCs) – this notice of funding opportunity (NOFO) RFA-AI-28-002 - HIV/AIDS Clinical Trials Network Laboratory Centers (LCs) RFA-AI-28-003 - HIV/AIDS Clinical Trials Network Statistical and Data Management Centers (SDMCs) RFA-AI-28-004 - HIV/AIDS Clinical Trials Network Clinical Trials Units (CTUs) While the emphasis of each Network is on clinical trials, clinical research studies that are not NIH-defined clinical trials are also in scope when undertaken to support the program. For this NOFO, the term "clinical study" refers to both clinical trials and clinical research studies, and "clinical trial" is used to refer to a clinical trial only.

NIAID plans to fund one LOC award for each Network, with one LOC per research agenda described below.

Each Clinical Trials Network will have an Executive Management Committee (EMC), established by the LOC, to coordinate the activities of the Network's LOC, LC and SDMC.

NIAID is responsible for the oversight and safety of all study participants in clinical trials funded by NIAID and will provide NIAID-convened Data and Safety Monitoring Boards (DSMBs) to monitor clinical trials. NIAID will provide additional support services for Network trials under an Investigational New Drug (IND) or Investigational Device Exemption (IDE).

Leadership and Operations Center Specific Responsibilities Each LOC will oversee one research agenda and will be responsible for the prioritization, planning, and conduct of studies in a HIV/AIDS Clinical Trials Network. The Networks will conduct studies to evaluate innovative strategies, as well as conduct implementation science research for established strategies. Research on epidemiological, behavioral, and social aspects of preventive and therapeutic interventions will be incorporated where appropriate. It is expected that Network clinical studies will be conducted at domestic and/or international sites depending on access to appropriate populations, sufficient disease burden or event rates, and timely participant accrual. International sites can offer opportunities for benefit to Americans living with, or at risk for acquiring, HIV and other HIV-associated infections when the proposed research cannot be accomplished as effectively or efficiently through domestic sites alone. Specific responsibilities include:

Governance: Establish clear structures for communication, decision-making authority, collaboration, and resource distribution with NIAID, ICO partners, and external collaborators.
Research Agenda: Collaborate with LC and SDMC to set and refine scientific priorities, engage stakeholders, and ensure alignment with NIAID and NIH goals.
Innovation: Foster innovative approaches, including public-private partnerships, to advance HIV clinical research.
Community Engagement: Integrate community participation across Network activities.
Training and Mentoring: Provide comprehensive training and promote mentorship, including protocol training and support for early-career investigators.
Quality Management: Ensure compliance, study participant protection, and data integrity through robust Quality Assurance and Quality Control processes; support audits and inspections.
Clinical Operations: Manage and oversee clinical studies, including protocol development, site selection, progress tracking, and results dissemination, in coordination with Network partners.
Clinical Research Sites (CRSs) and Protocol-Specific Sites (PS): Establish efficient processes for identifying, qualifying, and approving sites to meet unique study needs.
Network Management: Develop policies, Standard Operating Procedures (SOPs), budgets, and communication plans; implement effective project management for efficient protocol conduct, study completion and to allow cross-network coordination and reporting.
Network Meetings: Hold annual meetings to share findings and facilitate collaborations, with participation from key Network personnel, NIH staff, and external advisors.

The Research Agendas for the four Networks are as follows:

1. HIV/AIDS Adult Therapeutics Clinical Trials Network – Responsible for supporting the advancement of therapeutics research toward the treatment and cure of adults living with HIV including implementation science and clinical research to improve the management of HIV-related co-morbidities, coinfections and aging. Key aspects to this research agenda include:

Implementation Science - strategies to adapt, deliver, and expand the reach, scale-up, and sustainability of evidence-based treatment for HIV and HIV-associated diseases.

Novel and Durable Interventions for HIV – strategies to achieve durable HIV suppression and improve treatment outcomes for adults living with HIV.

Anti-retroviral (ART)-Free Remission (HIV Cure) - strategies to eradicate HIV or sustain virologic remission through immune-based interventions.

Complications and Non-Infectious Comorbidities – strategies to improve the prevention, treatment and management of high-impact co-morbidities in PWH (e.g., neurocognitive, substance use disorders, cardiovascular diseases, lung diseases, diabetic and related metabolic and endocrine conditions, kidney, urologic and hematologic disease, oropharyngeal complications, aging associated conditions).

Viral Hepatitis - novel treatment strategies for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.

Tuberculosis - novel therapeutics and combination treatments for drug-sensitive and -resistant tuberculosis (TB).

Additionally, this Network will be responsible for the clinical research infrastructure to support early-stage pilot trials of novel products and approaches; opportunities for intensive sampling of potential tissue reservoirs of HIV; and specialized laboratory capabilities for virologic and immunologic analyses.

2. HIV/AIDS Maternal, Adolescent, and Pediatric Clinical Trials Network – Responsible for advancing research to generate the evidence base on novel, innovative therapies, interventions, methods, and strategic approaches for HIV and HIV-associated conditions in infants, children, adolescents, and pregnant/postpartum women, integrating implementation science across the product development lifecycle to speed their adoption and scale-up. Key aspects to this research agenda include:

Implementation Science - strategies to adapt, deliver and scale evidence-based interventions that optimize prevention for pregnant and breastfeeding women, strengthen maternal antiretroviral therapy (ART), tailor infant prophylaxis, and expand early and repeat HIV testing for breastfeeding infants and children.

HIV Treatment and Prevention Innovations - antiretroviral drug and regimen innovations in appropriate long-acting (or pediatric-friendly oral) formulations for pediatric and maternal populations and infant postnatal prophylaxis.

ART-Free Remission (HIV Cure) - strategies to achieve sustained virologic remission in pediatric populations, including strategies initiated in the immediate newborn period.

Treatment and Prevention of Tuberculosis and Other HIV-associated Co-Infections - new drugs and regimens for treatment and prevention of drug-sensitive and resistant TB disease, both pulmonary and extrapulmonary (including central nervous system [CNS]); address treatment needs for congenital syphilis, viral hepatitis (B and C), and other important HIV-associated co-occurring infections.

Brain and Mental Health and Other HIV-associated Comorbidities - Neuroprotective and neurotoxic effects of ART to preserve neurocognitive development and mental health in infants, children, and adolescents. Evaluate novel preventive and therapeutic approaches for other high-priority diseases and co-occurring conditions

3. HIV Prevention Clinical Trials Network – Responsible for advancing products and strategies to meet the needs of populations vulnerable to HIV acquisition including adults, adolescents and pregnant women, through the integration of biomedical, socio-behavioral and structural prevention strategies, in partnership with implementing agencies and organizations. Key aspects to this research agenda include:

Implementation Science – strategies to optimize deployment of and improve access to biomedical and socio-behavioral evidence-based interventions for HIV prevention.

Integrated Prevention Strategies - integration of socio-behavioral research to optimize HIV prevention outcomes tailored to the population and context, to improve HIV treatment uptake and adherence, retention in care, and reduction of HIV risk.

Novel Biomedical HIV Prevention and Delivery Systems - strategies and delivery methods that meet the needs of varied populations and help address the challenges of adherence. Multipurpose technologies (MPTs) – products designed to simultaneously protect against multiple sexual and reproductive health issues and potentially medications to treat or prevent other health conditions.

Intersection of HIV and Other Sexually Transmitted Infections (STIs) - prevention and treatment strategies to address interaction between HIV and STIs.

4. Immune-Based Prevention Trials Network – Responsible for the discovery and advancement of immune-based strategies to protect against HIV infection and associated infectious diseases, including TB and STIs, through Phase 1–3 clinical trials designed to answer key immunologic research questions to inform future candidate design, define correlates of protection, and identify safe and efficacious preventative regimens. Key aspects to this research agenda include:

Antibody-Mediated Prevention for HIV - design and conduct Phase 1–3 trials of passive immunization strategies.

Induced-Immunity for Prevention of HIV Acquisition - evaluate immunogens, immune modulators and adjuvants; and combinations of immunogens with antiretroviral drugs and other HIV prevention modalities. Conduct rapid, iterative "discovery medicine" trials to evaluate novel immunogens and adjuvants.

Analytical Treatment Interruption (ATI) Strategies - studies in PWH to evaluate viral control to inform HIV immune-based prevention approaches and immunotherapy development.

Immune-based Prevention Strategies Against Other HIV-associated Infectious Diseases - evaluate interventions against other infectious diseases (e.g., TB and STIs) and how these diseases may influence the safety and effectiveness of HIV prevention approaches.

Integration of Implementation and Behavioral Science Research - integration across all stages of immune-based product development and evaluation, assessing acceptability and mode of intervention.

Determinants of Immune Function and Intervention Effectiveness - evaluate how the microbiome, diet and environmental exposures share or alter immune function and the effectiveness of prevention interventions.

Cross-Network Collaboration: Each Network will be expected to collaborate with other HIV/AIDS Networks and lend its expertise where other Networks serve as the lead. Opportunities for cross-network research collaboration will be developed post-award in conjunction with NIAID and other NIH staff.

Other Research Areas: Each Network may have the opportunity to contribute to the research agenda for support of the development of strategies, interventions, and products for the rapid response against other/emerging infectious diseases (not listed above) of public health importance and to implement clinical trials in support of this agenda. The research agenda for those efforts will be developed post-award through cross-network, joint leadership efforts in conjunction with NIAID and other NIH staff.

Core and Protocol Funds Funding to carry out the Network's research agenda falls into two categories:

Core Funds: initial fixed-base funding for infrastructure and salary support that is not protocol-specific. NIAID will provide core funds directly to the LOC, LC, SDMC and Network-affiliated CTUs on an annual basis.

Protocol Funds (PF): support to conduct protocols, including protocol-specific infrastructure or other requirements needed to conduct protocols at a clinical research site. PF varies annually, depending on costs of ongoing protocols. NIAID anticipates providing PF directly to the LOC, LC, SDMC and Network-affiliated CTUs on an annual basis.

The LOC will estimate PF needs for the Network (salary and non-salary PF) based on communications with the LC, SDMC and CTUs/CRSs and submit an annual budget request to NIAID.

During the project period, additional protocol-specific (PS) sites may be added as needed to execute a specific protocol. These will be reviewed individually and, if approved, supported via a vendor agreement. These PS sites will be closed upon completion of the protocol.

Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this NOFO.

Application Types Allowed

New

Renewal - Renewals of RFA-AI-19-003, RFA-AI-19-004, RFA-AI-19-005, and RFA-AI-19-006

The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.

Clinical Trial?

Required: Only accepting applications that propose clinical trial(s).

Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards

NIAID and partner components intend to commit an estimated total of $48M to fund 4 awards in FY2028.

Award Budget

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Award Project Period

The project period must be 7 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions - Includes all types
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education

Nonprofits Other Than Institutions of Higher Education

Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

Small Businesses
For-Profit Organizations (Other than Small Businesses)

Local Governments

State Governments
County Governments
City or Township Governments
Special District Governments
Indian/Native American Tribal Governments (Federally Recognized)
Indian/Native American Tribal Governments (Other than Federally Recognized)

Federal Governments

Eligible Agencies of the Federal Government

U.S. Territory or Possession

Other

Independent School Districts

Public Housing Authorities/Indian Housing Authorities

Native American Tribal Organizations (other than Federally recognized tribal governments)

Faith-based or Community-based Organizations

Regional Organizations

Foreign Organizations/Foreign Collaborations

Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.

Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

Required Registrations

Applicant Organizations Applicant organizations must complete and maintain the following registrations as described in the How to Apply - Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications for additional information System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. Foreign organizations must obtain a NATO Commercial and Government Entity (NCAGE) Code (in lieu of a CAGE code) in order to register in SAM. Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.

eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
Grants.gov – Applicants must have an active SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. Obtaining an eRA Commons account can take up to 2 weeks.

All PD(s)/PI(s) must be registered with ORCID. The personal profile associated with the PD(s)/PI(s) eRA Commons account must be linked to a valid ORCID ID. For more information on linking an ORCID ID to an eRA Commons personal profile see the ORCID topic in our eRA Commons online help.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide.

2. Cost Sharing This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement NIH Grants Policy Statement Section 1.2 Definition of Terms.

3. Additional Information on Eligibility Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Section IV. Application and Submission Information

1. Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice, or other notice from NIH Guide for Grants and Contracts). Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Page Limitations All page limitations described in the How to Apply – Application Guide and the Table of Page Limits must be followed, with the following additional instructions:

The Research Strategy must consist of the following sub-sections with the indicated page limits:

Sub-section A. Overview of the Proposed Leadership and Operations Center (LOC), one required - 12 pages Sub-section B. Scientific Leadership: Structure and Governance, one required - 12 pages Sub-section C. Clinical Research Agenda, one required - 30 pages Sub-section D. Training and Mentoring, one required - 6 pages Sub-section E. Evaluation and Improvement, one required - 6 pages Sub-section F. Quality Management, one required - 12 pages Sub-section G. Clinical Operations, one required - 30 pages Sub-section H. Collaboration with the LC, SDMC and CTUs/CRSs, one required - 12 pages Sub-section I. Communication, Collaboration and Harmonization, one required - 6 pages

Instructions for Application Submission

The following section supplements the instructions found in the How to Apply – Application Guide and should be used for preparing an application to this NOFO.

SF424(R&R) Cover All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

SF424(R&R) Other Project Information

SF424(R&R) Senior/Key Person Profile All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Within the Common Forms for Biographical Sketch and NIH Biographical Sketch Supplement, highlight the following:
The relevant experience in leading and managing a complex clinical research program, including the roles and responsibilities served. Describe relevant expertise in protocol design, regulatory compliance, site selection, study implementation and coordination.
The project management staff describe the experience, including roles and responsibilities served, and resource management expertise for clinical research programs of similar size and scope.

R&R Budget All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Only request Core Funds for the initial fixed-base funding, infrastructure and salary support that is not protocol-specific (e.g., administrative and management support, community education and engagement structures and activities, clinical quality management activities, record retention).

Do not request Protocol Funds (PF) (e.g., protocol-specific personnel salary, participant recruitment and retention, protocol required tests and evaluations, participant reimbursement, community education and engagement structures and activities, and protocol specimen shipment and storage).

If a single PD/PI is proposed, the PD/PI will be required to devote at least 6 person-months of effort to the project. If two or more PD(s)/PI(s) are named, each PD/PI must devote at least 3.6 person- months of effort to the project.

R&R Subaward Budget

PHS 398 Cover Page Supplement

PHS 398 Research Plan All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Specific Aims: Describe the scientific aims of the Leadership and Operations Center (LOC). Each application in response to this NOFO must address only the research agenda of one HIV/AIDS Clinical Trials Network and must state which one of the four HIV/AIDS Clinical Trials Networks the LOC proposes to support.

Research Strategy: The Research Strategy section must consist of sub-sections A-I as designated below.

Sub-section A. Overview of the Proposed Leadership and Operations Center (LOC)

Provide a high-level overview of the key clinical research questions and explain how the LOC research agenda will address them.
Describe the overall strategy and methodologies to be used to accomplish the specific aims of the LOC. Describe any novel (or refinements/improvements) in concepts, approaches, or methodologies that are being developed or used and any advantage that may have over existing methodologies with respect to the development, design, and conduct of clinical trials. Include approaches to the utilization of digital health tools and remote/decentralized trial capabilities to expand access and participation for study participants as needed for successful trial implementation.
Explain how the LOC will be integrated with the Laboratory Center (LC), Statistical and Data Management Center (SDMC) and Clinical Trials Units (CTUs) and leveraged to meet the goals of the overall Network.
Briefly explain how the use of international sites will directly inform interventions or strategies to benefit Americans living with, or at risk for acquiring, HIV and other HIV-associated infections.
For renewal applications: Progress Reports should be included in sub-section A.

Sub-section B. Scientific Leadership: Structure and Governance

Describe the overall LOC structure, including staffing roles and responsibilities, with an organizational chart identifying senior/key personnel, and describe how the LOC will interface with the LC, SDMC, and CTUs. Describe how this structure supports effective leadership of overall Network activities.
Describe the LOC governance framework, including decision-making committees (e.g., EMC), along with their composition, roles, and authorities.
Explain processes for setting priorities, adapting to evolving needs, aligning and reallocating Network resources, discontinuing unproductive activities, and exchanging scientific and programmatic information with NIH and stakeholders to assess progress and pursue new research and collaboration opportunities.

Sub-section C. Clinical Research Agenda

Describe key knowledge gaps and future opportunities in HIV research and outline a cohesive HIV clinical research agenda with clear goals, priority areas, benchmarks, and timelines.
For each research agenda area that the LOC will oversee, explain its relevance to the HIV field, its potential to address ongoing challenges and the key population characteristics required to support the work.
Describe how implementation science concepts will be incorporated, prioritized, and evaluated; outline strategies for embedding pre-implementation objectives in trials, transitioning from efficacy to effectiveness studies, testing strategies to improve engagement in care, and collaborating with partners to launch implementation studies.
Summarize the required scientific staff expertise, laboratory and site capabilities, community representation plans, and processes for integrating external expertise and novel ideas into the agenda.
Describe how the Network will leverage innovative trial designs and novel statistical methods to streamline trials and accelerate data generation.
Describe how the LOC structure will support rapid response to new scientific opportunities, how sub-studies and external investigator proposals will be reviewed and approved, and how access to specimens and data will be managed.
Describe the process for the incorporation of new researchers into the Network, within the context of conducting the Network's research agenda.
Outline processes and frequency for reviewing research priorities and concepts for merit and feasibility, obtaining external assessments, adjusting the agenda as needed, evaluating decision-making committees, and fostering partnerships with agencies, organizations, and industry to ensure access to needed tools and products.

For applications within the following Research Agendas, including the following:

1. HIV/AIDS Adult Therapeutics – Applications should describe:

Plans to incorporate discrete implementation studies or implementation research aims integrated into interventional clinical trials.
The infrastructure, expertise, and partnerships needed to identify and conduct high-priority implementation studies.
Plans to evaluate novel and durable interventions for HIV, with the integration of behavioral, biomedical and structural interventions, and how they would improve treatment outcomes and support long-term viral suppression in adults living with HIV.
The research plan for strategies intended to eradicate HIV or sustain virologic remission without continuous antiretroviral therapy.
Plans for clinical trials designed to improve prevention or management of major complications and comorbidities affecting people with HIV. Identify the targeted condition(s) and explain the expected clinical impact. Address the development of integrated care models to facilitate uptake into standards of care.
Plans for research on novel preventive or treatment strategies for HBV and/or HCV infection in the context of HIV.
Plans for research on tuberculosis (TB) in the context of HIV. Address novel therapeutics and combination regimens for drug-sensitive and drug-resistant TB disease, including extrapulmonary TB.
The evaluation strategies to maximize public health impact of interventions to prevent and treat HBV, HCV and TB disease among PWH.
How small proof of concept or Phase I (single site) clinical trials will be rapidly implemented when trials of high priority are identified.
How treatment-related protocols will incorporate valid assessments of treatment adherence, strategies to promote adherence to clinical trial protocols and investigational therapies, and concurrent scientific expertise.

2. HIV/AIDS Maternal, Adolescent, and Pediatric – Applications should describe:

Plans to advance implementation science for maternal, pediatric, and adolescent populations through contextually appropriate strategies to scale evidence-based interventions in real-world care settings. Describe use of hybrid effectiveness-implementation designs and approaches to identify children, link them to care, improve ART coverage and viral suppression and address multilevel barriers and facilitators to equitable adoption and scale-up.
How the Network will accelerate evaluation of antiretroviral innovations, including long-acting and pediatric-friendly oral formulations, in maternal and pediatric populations. Address postnatal prophylaxis strategies, including long-acting small molecules and biologic agents, for infants at high risk of vertical HIV acquisition.
Strategies to evaluate interventions aimed at pediatric ART-free remission, including very early diagnosis and treatment initiated in the newborn period, to improve future remission potential.
Plans to evaluate new drugs and regimens for treatment and prevention of drug-sensitive and drug-resistant TB, including pulmonary, extrapulmonary, and central nervous system disease, and to address unmet needs related to congenital syphilis, HBV, HCV, and other important HIV-associated coinfections.
Plans for research on brain and mental health and other HIV-associated comorbidities. Explain the relevance to HIV treatment and long-term developmental outcomes.

3. HIV/AIDS Prevention – Applications should describe:

How the Network will advance and expand implementation science for biomedical and socio-behavioral HIV prevention strategies by developing and evaluating approaches to scale evidence-based interventions for vulnerable populations. Explain how the proposed work will improve prevention reach, uptake, or sustainability.
How the proposed implementation science research includes health system approaches, use of real-world evidence, and validated implementation science frameworks, in partnership with local stakeholders, including community representatives and implementers.
Plans for integrated prevention packages that combine biomedical and socio-behavioral approaches tailored to specific populations and contexts and designed to improve prevention uptake, adherence, retention in services, reduction of HIV risk, and engagement in comprehensive health services. Describe how such strategies will be delivered across varied venues and service platforms to overcome structural and systems-level barriers.
Plans to evaluate novel biomedical HIV prevention interventions and delivery systems, including long-acting agents, sustained-release systems, and other innovative products or methods that increase choice and address adherence challenges. Include strategies to assess end-user preferences and preferred product characteristics to inform intervention development and optimization.
Clinical product development activities for MPTs, including methods to determine end-user preferred characteristics.
STI prevention or treatment strategies that include novel agents, point-of-care diagnostics, or biomarkers of adherence to STI prevention and treatment products. Explain how the proposed work addresses the interaction between HIV and STIs and improves prevention or treatment outcomes.

4. Immune-Based Preventions – Applications should describe:

Plans for clinical trials of antibody-mediated HIV prevention strategies. Address approaches to define protective antibody titers and functional characteristics, including pharmacokinetics, tissue distribution, and other features relevant to prevention.
Plans for clinical trials of induced-immunity approaches to prevent HIV acquisition in adult and pediatric populations, including the evaluation of immunogens, immune modulators, adjuvants, and combinations with antiretroviral drugs and other prevention modalities.
How the Network will conduct rapid, iterative discovery medicine trials to evaluate novel immunogens and adjuvants designed to induce protective immunity and the approaches to assess the durability of immune responses to inform the design of optimal boosting strategies.
How the Network will conduct carefully designed ATI studies in people with HIV to evaluate viral control and inform immune-based prevention and immunotherapy development.
Plans for immune-based prevention trials against other HIV-associated infectious diseases, including TB and STIs, including a focus on how these infections may affect the safety and effectiveness of immune-based HIV prevention approaches.
How implementation and behavioral science will be incorporated across all stages of immune-based product development. Address acceptability, mode of intervention, vulnerable populations, community perceptions and explain how these factors will inform product development and trial conduct.
Plans for evaluating how the microbiome, diet, and environmental exposures shape or alter immune function and the effectiveness of prevention interventions.

Sub-section D. Training and Mentoring Describe how the training needs (e.g., Network-specific, NIAID-mandated, protocol specific, site activation, etc.) of LOC scientific staff will be determined, provided and evaluated, and how necessary changes in training will be decided and implemented. Discuss how the LOC will coordinate across the Network to ensure appropriate training needs are met.

Provide plans for clinical research mentoring opportunities and integration of early-career investigators.

Sub-section E. Evaluation and Improvement Describe how the performance of the LOC will be evaluated and improved over the award period. Describe the process for re-evaluation of operational performance of the overall Network in the conduct of Network activities, including the financial management of Network resources. Provide the criteria for reallocation, if necessary, of resources to ensure efficient resource management. Include a discussion of metrics that may be used to determine both productivity and quality of the results generated by the Network over the duration of the award. Describe processes for the resolution of performance problems for the Network and proposed processes for the remediation/improvement of performance. Do not name or contact anticipated collaborators; rather, list areas of expertise that will be sought, frequency of assessments, etc.

Sub-section F. Quality Management Describe the approach to quality management for LOC activities and LOC-coordinated management of efforts of the SDMC, LC and CTUs/CRSs needed for achieving and maintaining compliance with International Council for Harmonization E6 (ICHE6), 21CFR Part 11, Good Documentation Practice (GDP), Good Manufacturing Practice (GMP), Division of AIDS (DAIDS) Clinical Research Policies and Standard Operating Procedures (SOPs), and other standards.

Describe the coordination of the overall LOC Quality Management Plan with individual quality plans developed for each protocol. Address quality control procedures including real time systemic checks of protocol and regulatory adherence; quality assurance including regular auditing, and quality improvement based on evaluation and education.

Sub-section G: Clinical Operations Organizational Structure and Management Plan Describe the LOC Clinical Operations structure and functions, including day-to-day management, coordination of scientific and fiscal responsibilities, financial oversight of Network resources, cost-efficiency strategies, and processes for soliciting and managing subcontracts and acquired services.

Protocol Development and Project Management Outline the end-to-end protocol development process–from concept approval through NIAID approval and site distribution–ensuring compliance with applicable policies and regulations (including NIAID clinical research policies and SOPs, ICHE6, and 21 CFR Part 11); define team composition, roles, decision-making processes, budget development, resource allocation, benchmark tracking, contingency planning, and expedited pathways for high-priority studies.

Describe how protocol budgets will be developed and how protocol funding will be linked to resource requirements. Describe the process for determination of salary and non-salary PF allocation to the CTUs/CRSs.

Clinical Research Site Selection Describe the approach to assessing and selecting clinical research sites, addressing capacity gaps (including adding non-Network sites when necessary), and ensuring transparent coordination with NIAID, CTUs/CRSs, affiliated laboratories, and clinical research support programs.

Protocol Implementation and Performance Oversight Explain strategies for implementing and completing protocols on time and within budget, integrating NIAID contract resources, fast-tracking high-priority studies, delivering protocol-specific training, monitoring study progress, evaluating site performance, and addressing underperformance.

Sub-section H. Collaboration with LC, SDMC and CTUs/CRSs Describe plans, processes and procedures for interacting and collaborating with the LC. Describe the collaboration with the LC in the evolution of the research agenda, and in development and implementation of protocols. Describe the process for projecting needs and costs for laboratory services including capacity to conduct routine and protocol-specific laboratory assays, conduct laboratory activation and training, and provide repository services. Describe plans for LC involvement with local, regional and specialty laboratories. Describe the process for tracking actual use of protocol-specific laboratory services compared to projected needs and adjusting capacity.

Describe plans, processes and procedures for interacting and collaborating with the SDMC. Discuss how the LOC will facilitate the use of data systems by the SDMC that are compliant with 21 CFR and ICH guidelines. Describe coordination of activities with the SDMC staff including, but not limited to: protocol design, development and implementation, data analysis, preparation of data summaries (within and across protocols), and publication of results. Describe plans for coordination of responsibilities of the LOC and SDMC in study preparation at the data management and site level including protocol-specific training.

Describe how the LOC will interact and collaborate with the CTUs and CRSs, including the following:

Conducting site feasibility assessments to evaluate capacity, capabilities, laboratory access, pharmacy security, and ability to recruit and retain the target population(s).
Soliciting, reviewing, and selecting CRSs to implement specific protocols based on objective criteria. Establishing timelines for protocol activation and developing procedures for protocol-specific training to ensure readiness and consistent study conduct across CRSs.
Managing study products; verifying laboratory and specimen management capabilities; ensuring capacity for data collection, analysis, and secure transmission to the SDMC.
Providing participant safety oversight and regulatory compliance.
Establishing decision-making processes for modifying or reducing site capacity, including site closure if necessary.

Sub-section I. Communication, Collaboration and Harmonization Describe processes for Network-wide communications. Include plans for communicating and publishing results from Network research.

Describe plans for community engagement, including a description of the role and nature of community input, from individuals and from groups, in all aspects of the Network. Do not name or contact specific community-based organizations (CBOs) and non-government organizations (NGO) community advisors or organizations. Do provide the names, expertise/experience, roles and responsibilities of paid LOC staff who will be involved in community activities.

Describe how the LOC will work with other Network LOCs to ensure efficient utilization of NIH resources to address cross-network hypotheses and endpoints. Specifically include plans to develop, implement and oversee clinical trials that address scientific questions of mutual interest.

Provide a detailed plan to work with other LOCs, SDMCs, and LCs to identify and harmonize processes for working with CTUs and CRSs.

Letters of Support:

Provide appropriate letters of support limited to collaborators who have a significant role in the application. Note that letters establishing intra-network and cross-network collaborations are not necessary.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply - Application Guide.

Other Plan(s):

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

A Data Management and Sharing Plan (DMS Plan) is required for any NIH-funded or conducted research that will generate scientific data. Applicants must submit the DMS Plan at the time of application using the NIH DMS Plan Format Page. The DMS Plan must address the elements in the structured format. Where the DMS Plan Format Page requires a "Yes or No" response, no additional narrative is allowed.

This is the start of the file's text. The full file is on GovTribe.

Other files

File Type Posted
PKG00294600.pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

File details come from the government source that posted it. Updated .